MedTrace Logo

HER2 Expression Detection in Breast Cancer Using 99mTc-NM-02

NCT04040686 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-04-14

No results posted yet for this study

Summary

A 99mTc-labeled anti-HER2-sdAb (99mTc-NM-02) will be developed for SPECT/CT assessment of HER2 expression in breast cancer patients. Its safety, radiation dosimetry and biodistribution, and the relationship between tumor uptake and HER2 immunohistochemistry results will be investigated.

Conditions

Interventions

DRUG

Injection of 99mTc-NM-02

Patient will be injected with microdose (\<100ug) of 99mTc-NM-02 radiotracer

Sponsors & Collaborators

  • NanoMab Technology (UK) Limited

    collaborator INDUSTRY

  • Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

    lead OTHER

Principal Investigators

  • Jinhua Zhao, PhD · Shanghai General Hospital Nuclear Medicine Dept

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-29
Primary Completion
2021-12-31
Completion
2022-03-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04040686 on ClinicalTrials.gov